Largo R, Heller V, Straub P W
Blood. 1976 Jun;47(6):991-1002.
The presence of minimal amounts of fibrinogen-fibrin intermediates in human plasma was visualized by an agglutination reaction of glutaraldehyde-treated human erythrocytes coated with purified fibrin monomers. A degree of monomer coating was established which produced erythrocytes not agglutinated by normal plasma but by plasma containing minimal amounts of soluble complexes of fibrinogen with fibrin monomers. Under standardized conditions of coating, erythrocyte concentration, temperature, pH, and incubation time, the agglutination time varied with the ratio of soluble fibrin to fibrinogen in plasma. The test was sensitive down to a soluble fibrin concentration of 0.675% of the plasma fibrinogen concentration. Early fibrinogen and fibrin degradation products (FDP) in the plasma led to a prolongation of the agglutination time at a concentration of more than 16 mg/100 ml. Late FDP in a concentration of 100 mg/100 ml did not convert a positive test to negative. The test was not affected by heparin and protamine at concentrations of up to 12.5 and 50 NIH units/ml, respectively.
通过用纯化的纤维蛋白单体包被的戊二醛处理的人红细胞的凝集反应，可观察到人血浆中极少量纤维蛋白原 - 纤维蛋白中间体的存在。确定了一定程度的单体包被，这种包被产生的红细胞不会被正常血浆凝集，但会被含有极少量纤维蛋白原与纤维蛋白单体可溶性复合物的血浆凝集。在包被、红细胞浓度、温度、pH值和孵育时间的标准化条件下，凝集时间随血浆中可溶性纤维蛋白与纤维蛋白原的比例而变化。该测试对可溶性纤维蛋白浓度低至血浆纤维蛋白原浓度的0.675%仍敏感。血浆中早期纤维蛋白原和纤维蛋白降解产物（FDP）在浓度超过16mg/100ml时会导致凝集时间延长。浓度为100mg/100ml的晚期FDP不会使阳性测试转为阴性。该测试分别在高达12.5和50 NIH单位/ml的浓度下不受肝素和鱼精蛋白的影响。
